Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (350)

2023

  1. Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19

    Infectious Diseases Now, Vol. 53, Núm. 7

  2. Differences in the inflammatory response among hospitalized patients with distinct variants of SARS-CoV-2

    Frontiers in Immunology, Vol. 14

  3. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

    EBioMedicine, Vol. 95, pp. 104773

  4. Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

  5. Gut Microbiota and Derived Short-Chain Fatty Acids Are Linked to Evolution of Heart Failure Patients

    International journal of molecular sciences, Vol. 24, Núm. 18

  6. Gut microbiota profiles in feces and paired tumor and non-tumor tissues from Colorectal Cancer patients. Relationship to the Body Mass Index

    PLoS ONE, Vol. 18, Núm. 10 OCTOBER

  7. Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study

    The Lancet Microbe, Vol. 4, Núm. 1, pp. e21-e28

  8. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  9. Non-invasive electromechanical assessment during atrial fibrillation identifies underlying atrial myopathy alterations with early prognostic value

    Nature communications, Vol. 14, Núm. 1, pp. 4613

  10. Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  11. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors

    Biomedicines, Vol. 11, Núm. 4

  12. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701

  13. TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

    Thorax, Vol. 78, Núm. 8, pp. 816-824